Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) – a sustained-release pre|CISION® exatecan peptide drug conjugate
Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected…
